Alzheimer's disease

Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's
Biogen chalks up another failure, but investors' eyes remain firmly on Alzheimer's
Fierce Biotech
Biogen
Alzheimer's disease
aducanumab
progressive supranuclear palsy
gosuranemab
clinical trials
Flag link:
Grifols says trial shows positive effects in slowing Alzheimer's
Grifols says trial shows positive effects in slowing Alzheimer's
Reuters
Grifols
Alzheimer's disease
clinical trials
Flag link:
Biohaven Pharma to continue late-stage study of Alzheimer's treatment
Biohaven Pharma to continue late-stage study of Alzheimer's treatment
Reuters
Biohaven Pharmaceuticals
Alzheimer's disease
troriluzole
Flag link:
Biogen Points to Enrollment and Dosing to Explain Alzheimer’s Results
Biogen Points to Enrollment and Dosing to Explain Alzheimer’s Results
Xconomy
Biogen
Alzheimer's disease
aducanumab
Worldwide Clinical Trials
Flag link:
The clearest picture of Biogen's Alzheimer's drug is still fuzzy
The clearest picture of Biogen's Alzheimer's drug is still fuzzy
Biopharma Dive
Biogen
Alzheimer's disease
clinical trials
aducanumab
Flag link:
New Biogen data showed no major safety issues for its Alzheimer's drug
New Biogen data showed no major safety issues for its Alzheimer's drug
Reuters
Biogen
safety
Alzheimer's disease
aducanumab
clinical trials
Flag link:
6 Experimental Alzheimer’s Disease Diagnostics Projects Get Funding Boost
6 Experimental Alzheimer’s Disease Diagnostics Projects Get Funding Boost
Xconomy
Alzheimer's disease
diagnostics
DiamiR Biosciences
RetiSpec
Flag link:
What to watch as Biogen presents its all-important Alzheimer's data
What to watch as Biogen presents its all-important Alzheimer's data
Biopharma Dive
Biogen
clinical trials
Alzheimer's disease
aducanumab
Flag link:
Biogen’s stock could fall 10% on new Alzheimer’s drug data this week, top analyst says
Biogen’s stock could fall 10% on new Alzheimer’s drug data this week, top analyst says
CNBC
Biogen
Alzheimer's disease
aducanumab
Flag link:
Analyst: Biogen's aducanumab is not getting approved absent a deus ex machina
Analyst: Biogen's aducanumab is not getting approved absent a deus ex machina
Fierce Biotech
Biogen
aducanumab
FDA
Alzheimer's disease
Flag link:
Why Biogen's Recent Rebound May Not Last -- at Least for Now
Why Biogen's Recent Rebound May Not Last -- at Least for Now
Motley Fool
Biogen
MS
multiple sclerois
Alzheimer's disease
Tecfidera
aducanumab
Flag link:
Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug
Biogen’s top scientist nearly dares FDA not to approve Alzheimer’s drug
Stat
Biogen
aducanumab
FDA
Alzheimer's disease
Flag link:
Roche tests 'brain shuttle' in humans in Alzheimer's project
Roche tests 'brain shuttle' in humans in Alzheimer's project
Reuters
Roche
Alzheimer's disease
monoclonal antibodies
gantenerumab
Flag link:
Here's Why Biogen Stock Shot Up 28% in October
Here's Why Biogen Stock Shot Up 28% in October
Motley Fool
Biogen
Alzheimer's disease
aducanumab
Flag link:
China's Alzheimer’s Drug Approval Raises Hopes and Skepticism
China's Alzheimer’s Drug Approval Raises Hopes and Skepticism
BioSpace
Alzheimer's disease
China
Shanghai Green Valley Pharmaceuticals
Flag link:
Chinese pharma claims first Alzheimer’s drug approval since 2003
Chinese pharma claims first Alzheimer’s drug approval since 2003
Pharmaforum
China
Alzheimer's disease
Shanghai Green Valley Pharmaceuticals
Oligomannate
Flag link:
Small Alzheimer's hopeful biotech nabs $15M series B for metabolic drug approach
Small Alzheimer's hopeful biotech nabs $15M series B for metabolic drug approach
Fierce Biotech
T3D Therapeutics
NIH
Alzheimer's disease
Flag link:
Research Roundup: What Are Microproteins and What Do They Do and More
Research Roundup: What Are Microproteins and What Do They Do and More
BioSpace
microproteins
Alzheimer's disease
universal flu vaccine
R&D
Flag link:
Allergan pays $750m to avoid Alzheimer’s drug lawsuit
Allergan pays $750m to avoid Alzheimer’s drug lawsuit
Pharmaforum
Allergan
Namenda
Alzheimer's disease
settlement
Flag link:
Biogen Alzheimer's Case Shows Danger of Trials Killing Good Drugs
Biogen Alzheimer's Case Shows Danger of Trials Killing Good Drugs
Yahoo/Guru Focus
Biogen
Alzheimer's disease
aducanumab
clinical trials
drug development
Flag link:

Pages